Clinical Trial

Peri-operative Treatment of Resectable Gastroesophageal Cancer Using Bemarituzumab (BEMA) Plus Perioperative Treatment

Study acronym: NeoBEMA
Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is an open-label,multi-centre, phase 1b safety and feasibility study aiming to assess the safey and feasibility of bemarituzumab plus chemiotherapy (FLOT) for the peri-operative treatment of resectable gastroesophageal cancer. Following this neo-adjuvant part, patients should undergo surgery. Following surgery, patients will receive FLOT chemotherapy in combination with bemarituzumab. Imaging will be performed every 3 months for the first 2 years and thereafter every 6 months as per standard of care.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-05-09; most recent amendment 2025-06-02.
Trial Details
NCT Number NCT06978062
Lead Sponsor European Organisation for Research and Treatment of Cancer - EORTC
Conditions GastroEsophageal Cancer
Enrollment 27 participants
Start Date 2026-02-20
Primary Completion 2028-09-11 (estimated)
Study Completion 2029-09-28 (estimated)
Updated on ClinicalTrials.gov 2025-06-05